Shinichi Imafuku

Jul 16, 2023 | jofskin.org | Melinda Gooderham |Lynda Spelman |Shinichi Imafuku |Marco Romanelli

Main Article Content Keywords Deucravacitinib, Plaque Psoriasis Abstract Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the US and other countries for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In the POETYK PSO-1 (NCT03624127) and PSO-2 (NCT03611751) trials, deucravacitinib was superior to placebo and apremilast in patients with moderate to severe plaque...

Mar 13, 2023 | jofskin.org | Mark Lebwohl |Richard Warren |Howard Sofen |Shinichi Imafuku

Main Article Content Keywords psoriasis, deucravacitinib, tyrosine kinase 2, phase 3 clinical trial, efficacy, long-term Abstract Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved by the US Food and Drug Administration for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. In the pivotal phase 3 POETYK PSO-1 trial, deucravacitinib was superior to placebo and apremilast...